We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 422.70
Bid: 420.70
Ask: 421.00
Change: 9.80 (2.37%)
Spread: 0.30 (0.071%)
Open: 407.00
High: 422.70
Low: 403.90
Prev. Close: 412.90
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

18 Apr 2019 07:00

RNS Number : 5559W
Rentokil Initial PLC
18 April 2019
 

 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

18 April 2019

 

(£m)

 

Q1 2019

Growth

 

 

AER

AER

CER

Ongoing Revenue1

 

603.6

10.6%

8.9%

Revenue

 

607.4

10.3%

8.6%

 

Overview

Trading has started well across our businesses in Q1 with Ongoing Revenue1 increasing by 8.9%, of which 4.0% was Organic Revenue2 growth (Q1 2018: 3.2%, FY 2018: 3.7%) and 4.9% was from acquisitions.

Ongoing Revenue in Pest Control grew by 12.0%, 5.0% Organic (Q1 2018: 4.7%), with good performances being delivered across both Growth and Emerging markets, which rose by 12.1% and 11.5% respectively. Hygiene has made a very positive start to the year, with Ongoing Revenue growth of 7.2% and Organic Revenue growth of 4.3% (Q1 2018: 1.8%). Ongoing Revenue in our Protect & Enhance markets was in line with Q1 2018.

M&A

​We signed eight acquisitions in Q1, four in Pest Control (primarily in North America and Latin America) and four in Hygiene, with combined annualised revenues of c. £29m in the year prior to purchase. We are encouraged about our prospects for further M&A this year and our pipeline of value-enhancing opportunities is strong. Our guidance for M&A spend in 2019 remains in the range of £200m to £250m.  

Pension Scheme and Funding

In December 2018 the Company reached agreement for a bulk annuity insurance 'buy-in' for its UK Defined Benefit Pension scheme ("the Scheme") in contemplation of a full 'buy-out' which is expected to complete in early 2020. Good progress towards buy-out is being made and we now anticipate a pre-tax cash surplus of c. £40m will be returned to the Company on completion.

Ahead of the refinancing of our €500m bond maturing in September this year, we are intending to hold a non-deal, bond investor education roadshow in London, France, Germany, the Netherlands, Nordics and Asia. We will release further details in due course.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have had a good start to 2019 and I'm pleased with our performance in the first three months of this year. I am confident of another year of successful growth for the Company, in line with market expectations."

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

 

 

 

 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

 

 

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2018 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTZMGMDRNMGLZM
Date   Source Headline
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company
14th Oct 20224:39 pmRNSHolding(s) in Company
14th Oct 20224:37 pmRNSHolding(s) in Company
14th Oct 20229:30 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.